After many years of research and development, ATANIS Biotech AG was incorporated as a spinoff of the University of Bern in June 2021. The four co-founders Noemi Zbären, Jean-Pierre Kinet, Thomas Kaufmann and Alexander Eggel bring >70 years of combined experience in basic and clinical allergy research, cell and molecular biology and diagnostic assay development to the company and have published >250 publications in peer-reviewed high-impact journals.
Our team
Prof. Dr. Jean-Pierre Kinet
Co-Founder & CEO
Erwan Eriau
Chief Operating Officer
Jonathan Friedlander
Chief Business Officer
Dr. Saskia Agten-Brunner
Head of Diagnostic Laboratory
Robin van Brummelen
Head of Research Services
Dr. Julia Tischler
Head of Process Technology
Antonia Ferreira
Development Scientist
Giulia Fuchs
Research Associate
Marianne Zwicker
Laboratory Manager
Dr. Lucas Degrugillier
Head of Design & Development
Eloi Thauvin
Manufacturing and Improvement Engineer
Joëlle Schläfli
Manufacturing and Quality Control Engineer
Prof. Dr. Thomas Kaufmann
Co-Founder & Scientific Advisor
Prof. Dr. Alexander Eggel
Co-Founder & Scientific Advisor
Jascha Forster
Board member
Mária Husvéth-Tóth
Research Assistant
Dr. Zahra Gharailoo
Research Scientist
Jessica Almeida Oliveira
Development Associate
Juliette Assenmacher
Development Associate
Melanie Devjayanth
QA Release Assistant
Our Customers
Our customer base reaches from highly established industrial partners to individual research groups.

Excellergy
Excellergy is a biotechnology company developing new therapeutic modalities in various diseases.
Our Investors
Are you interested to invest in ATANIS Biotech AG or to financially support us? Please get in touch!



